Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
oleh: Valentín Ortiz-Maldonado, Valentín Ortiz-Maldonado, Gerard Frigola, Marta Español-Rego, Olga Balagué, Olga Balagué, Nuria Martínez-Cibrián, Laura Magnano, Laura Magnano, Eva Giné, Eva Giné, Eva Giné, Mariona Pascal, Juan G. Correa, Alexandra Martínez-Roca, Joan Cid, Joan Cid, Miquel Lozano, Miquel Lozano, Miquel Lozano, Neus Villamor, Neus Villamor, Neus Villamor, Daniel Benítez-Ribas, Daniel Benítez-Ribas, Jordi Esteve, Jordi Esteve, Jordi Esteve, Jordi Esteve, Armando López-Guillermo, Armando López-Guillermo, Armando López-Guillermo, Armando López-Guillermo, Elías Campo, Elías Campo, Elías Campo, Elías Campo, Elías Campo, Álvaro Urbano-Ispizua, Álvaro Urbano-Ispizua, Álvaro Urbano-Ispizua, Álvaro Urbano-Ispizua, Manel Juan, Manel Juan, Manel Juan, Julio Delgado, Julio Delgado, Julio Delgado, Julio Delgado
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2022-01-01 |
Deskripsi
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.